Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer

被引：165

作者：

Prelaj, Arsela ^{[1
,2
]}

Tay, Rebecca ^{[1
]}

Ferrara, Roberto ^{[3
]}

Chaput, Nathalie ^{[3
,4
]}

Besse, Benjamin ^{[5
,6
]}

Califano, Raffaele ^{[1
,7
,8
]}

机构：

[1] Christie NHS Fdn Trust, Wilmslow Rd, Manchester M20 4BX, Lancs, England

[2] Sapienza Univ Rome, Dept Radiol Pathol & Oncol Sci, Rome, Italy

[3] Gustave Roussy, Lab Immunomonitoring Oncol, CNRS, INSERM,UMS 3655,US 23, Villejuif, France

[4] Univ Paris Saclay, Fac Pharm, Chatenay Malabry, France

[5] Gustave Roussy, Canc Med Dept, Villejuif, France

[6] Paris Sud Univ, Orsay, France

[7] Manchester Univ NHS Fdn Trust, Dept Med Oncol, Manchester, Lancs, England

[8] Univ Manchester, Div Canc Sci, Manchester, Lancs, England

来源：

EUROPEAN JOURNAL OF CANCER | 2019年 / 106卷

关键词：

NSCLC; Immunotherapy; Predictive biomarkers; Lung cancer; PD-L1; Tumour mutational burden; Tumour microenvironment; Microsatellite instability; TO-LYMPHOCYTE RATIO; TUMOR-INFILTRATING LYMPHOCYTES; SUPPRESSOR-CELLS; PERIPHERAL-BLOOD; MUTATIONAL BURDEN; PD-1; BLOCKADE; SOLID TUMORS; OPEN-LABEL; INDEPENDENT PREDICTOR; COLORECTAL-CANCER;

D O I：

10.1016/j.ejca.2018.11.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune checkpoint blockade has been a pivotal development in the management of advanced non-small-cell lung cancer (NSCLC). Although durable antitumour activity and improved survival have been observed in a subset of patients, there is a need for additional predictive biomarkers to improve patient selection and avoid toxicity in potential non-responders. This review will address the use and limitations of tumour programmed death-ligand 1 expression as a predictive biomarker and review emerging biomarker strategies specifically related to NSCLC including genetic alterations (tumour mutation burden, loss and gain activated mutations), tumour-related factors (tumour microenvironment) and factors related to the host immune system. Novel approaches in biomarker detection such as peripheral blood monitoring will also be reviewed. (C) 2018 Elsevier Ltd. All rights reserved.

引用

页码：144 / 159

页数：16

共 150 条

[1] Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired [J].

Ahmadzadeh, Mojgan ;

Johnson, Laura A. ;

Heemskerk, Bianca ;

Wunderlich, John R. ;

Dudley, Mark E. ;

White, Donald E. ;

Rosenberg, Steven A. .

BLOOD, 2009, 114 (08) :1537-1544

[2] Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade [J].

Akbay, Esra A. ;

Koyama, Shohei ;

Liu, Yan ;

Dries, Ruben ;

Bufe, Lauren E. ;

Silkes, Michael ;

Alath, M. D. Maksudul ;

Magee, Dillon M. ;

Jones, Robert ;

Jinushi, Masahisa ;

Kulkarni, Meghana ;

Carretero, Julian ;

Wang, Xiaoen ;

Warner-Hatten, Tiquella ;

Cavanaugh, Jillian D. ;

Osa, Akio ;

Kumanogoh, Atsushi ;

Freeman, Gordon J. ;

Awad, Mark M. ;

Christiani, David C. ;

Bueno, Raphael ;

Hammerman, Peter S. ;

Dranoff, Glenn ;

Wong, Kwok-Kin .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (08) :1268-1279

[3] Clinical prognostic factors associated with outcome in patients with renal cell cancer with prior tyrosine kinase inhibitors or immunotherapy treated with everolimus [J].

Amato, Robert J. ;

Flaherty, Amber ;

Zhang, Yufeng ;

Ouyang, Fangqian ;

Mohlere, Virginia .

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (03) :345-354

[4] Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer [J].

Anagnostou, Valsamo ;

Smith, Kellie N. ;

Forde, Patrick M. ;

Niknafs, Noushin ;

Bhattacharya, Rohit ;

White, James ;

Zhang, Theresa ;

Adleff, Vilmos ;

Phallen, Jillian ;

Wali, Neha ;

Hruban, Carolyn ;

Guthrie, Violeta B. ;

Rodgers, Kristen ;

Naidoo, Jarushka ;

Kang, Hyunseok ;

Sharfman, William ;

Georgiades, Christos ;

Verde, Franco ;

Illei, Peter ;

Li, Qing Kay ;

Gabrielson, Edward ;

Brock, Malcolm V. ;

Zahnow, Cynthia A. ;

Baylin, Stephen B. ;

Scharpf, Robert B. ;

Brahmer, Julie R. ;

Karchin, Rachel ;

Pardoll, Drew M. ;

Velculescu, Victor E. .

CANCER DISCOVERY, 2017, 7 (03) :264-276

[5]

[Anonymous], 2016, J Immunother Cancer, DOI [10.1186/s40425-016-0191-4, DOI 10.1186/S40425-016-0191-4]

[6]

[Anonymous], 2017, CELL, V171, P1259

[7]

[Anonymous], ANN ONCOL, DOI [10.1093/annonc/mdx363.018, DOI 10.1093/ANNONC/MDX363.018]

[8] Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients [J].

Arrieta, Oscar ;

Montes-Servin, Edgar ;

Hernandez-Martinez, Juan-Manuel ;

Cardona, Andres F. ;

Casas-Ruiz, Eibar ;

Crispin, Jose C. ;

Motola, Daniel ;

Flores-Estrada, Diana ;

Barrera, Lourdes .

ONCOTARGET, 2017, 8 (60) :101994-102005

[9] Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma [J].

Azimi, Farhad ;

Scolyer, Richard A. ;

Rumcheva, Pavlina ;

Moncrieff, Marc ;

Murali, Rajmohan ;

McCarthy, Stanley W. ;

Saw, Robyn P. ;

Thompson, John F. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) :2678-2683

[10] Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer [J].

Bagley, Stephen J. ;

Kothari, Shawn ;

Aggarwal, Charu ;

Bauml, Joshua M. ;

Alley, Evan W. ;

Evans, Tracey L. ;

Kosteva, John A. ;

Ciunci, Christine A. ;

Gabriel, Peter E. ;

Thompson, Jeffrey C. ;

Stonehouse-Lee, Susan ;

Sherry, Victoria E. ;

Gilbert, Elizabeth ;

Eaby-Sandy, Beth ;

Mutale, Faith ;

DiLullo, Gloria ;

Cohen, Roger B. ;

Vachani, Anil ;

Langer, Corey J. .

LUNG CANCER, 2017, 106 :1-7

← 1 2 3 4 5 6 7 8 9 10 →